&nbsp;

Nov 2024

Drug

riTUXimab (subcut)

Other Name(s): Rituxan® SC

Quick Link(s):

Jun 2025

Drug

mitoXANTRONE

Other Name(s): Novantrone® (multiple brands available)

Quick Link(s):

May 2018

Regimen

RITU(DESENS)

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL),

Leukemia - Chronic Lymphocytic (CLL),

Leukemia - Hairy Cell,

Lymphoma - Hodgkin,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Curative, Palliative

Drugs Used:

trastuzumab

Quick Link(s):

Regimen Monograph

Jul 2025

Drug

riTUXimab

Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™

Quick Link(s):

Jun 2025

Drug

vinCRIStine

Other Name(s): Oncovin® (multiple brands available)

Quick Link(s):

Nov 2017

Regimen

FCM(PO)+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

ODB - General Benefit

cyclophosphamide - oral tablets

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

Drugs Used:

riTUXimab,

mitoXANTRONE,

fludarabine (Unfunded),

cyclophosphamide,

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Aug 2020

Drug

cyclophosphamide

Other Name(s): Procytox®

Quick Link(s):

Oct 2020

Regimen

CHLO+OBIN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma

ODB - General Benefit

chlorambucil

Drugs Used:

oBINutuzumab,

chlorambucil

Quick Link(s):

Regimen Monograph

Dec 2018

Regimen

ZANU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

zanubrutinib - For the treatment of relapsed or refractory Waldenström Macroglobulinemia, according to clinical criteria

Drugs Used:

zanubrutinib

Quick Link(s):

Regimen Monograph

Mar 2024

Regimen

FLUD+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2021

Regimen

FLUD(PO)+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used:

riTUXimab,

fludarabine (Unfunded),

riTUXimab (subcut)